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Angiogenesis, the formation of new 
blood vessels from pre-existing ones, is 
essential for the development of most solid 
tumors. While angiogenesis in normal tis-
sues is tightly coordinated by the activity 
of various anti- and pro-angiogenic fac-
tors, the formation of new blood vessels 
within neoplastic lesions is sustained by 
the imbalanced expression of pro-angio-
genic mediators.1 This generally involves 
a functional interplay between malignant 
cells and several of their non-malignant 
counterparts that populate the tumor 
microenvironment, including endothelial 
cells, pericytes, and fibroblasts. Tumor-
infiltrating bone marrow-derived cells 
(BMDCs), such as tumor-associated mac-
rophages (TAMs), Tie2-expressing mono-
cytes (TEMs), mast cells, granulocytes, 
dendritic cells, and myeloid suppressor 
cells, may also promote angiogenesis in 
the tumor microenvironment by produc-
ing soluble mediators that stimulate the 
proliferation, migration, and functional 
differentiation of endothelial cells.2,3 In 
addition, angiogenesis critically relies on 
several extracellular proteases that acti-
vate growth factors, inhibit suppressive 
mediators, and/or promote extracellular 
matrix (ECM) degradation along with tis-
sue remodeling.
We have previously shown that alanyl 
(membrane) aminopeptidase (ANPEP, 
best known as CD13) is one of the pro-
teolytic enzymes involved in angiogenesis 
and tumor growth.4 CD13 is a membrane-
bound metallopeptidase expressed in 
tumors by endothelial cells, pericytes and 
fibroblasts, as well as by some neoplastic 
cells. Different immunoreactive forms 
of CD13 are also expressed by many 
non-malignant cells of normal tissues, 
including some types of epithelial cells, 
keratinocytes, mast cells, myeloid cells, 
and antigen-presenting cells.5 In physi-
ological conditions, CD13 operates quite 
broadly in protein degradation, antigen 
presentation, signal transduction, dif-
ferentiation, proliferation, adhesion and 
migration, and also regulates various hor-
mones and cytokines.5 In addition, CD13 
has been involved in the epithelial-to-
mesenchymal transition, hence promoting 
tumor progression.5 Our group has shown 
CD13 to have a functional role in angio-
genesis both in normal and neoplastic 
tissues.4,6 In line with this notion, new-
born CD13-null mice exhibit a reduced 
angiogenic response to hypoxia in a model 
of oxygen-induced retinopathy of prema-
turity.6 Furthermore, adult CD13-null 
mice display reduced angiogenesis and 
limited tumor growth rates than their 
wild-type (WT) counterparts.4 Although 
these results indicated that CD13 par-
ticipates in pathological angiogenesis, the 
specific cell types involved were not iden-
tified in these studies.
To dissect the relative contributions of 
different CD13+ cells to abnormal angio-
genesis, we have recently investigated 
the growth of B16F10 melanomas, TSA 
mammary adenocarcinomas and Lewis 
lung carcinomas (LLC) subcutaneously 
implanted into 4 different syngeneic 
murine models: (1) WT mice transplanted 
with WT BMDCs recovered from isogenic 
donors (WTwt); (2) CD13-null (KO) mice 
transplanted with WT BMDCs (KOwt); 
(3) WT mice transplanted with CD13-
null BMDCs (WTko); and (4) CD13-
null mice transplanted with CD13-null 
BMDCs recovered from isogenic donors 
(KOko) (Fig. 1).7 Tumor growth was 
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severely impaired in mice lacking CD13+ 
BMDCs (WTko and KOko), correlating 
with a reduction in both vascular den-
sity and pericyte coverage within residual 
neoplastic lesions. Notably, the growth of 
TSA and LLC cells was restored in KOwt 
mice, which fail to express CD13 on peri-
cytes, endothelial cells and fibroblasts but 
are reconstituted with CD13+ BMDCs. 
Of note, the absence of CD13+ BMDCs 
in KOko and WTko mice markedly reduced 
the metastatic dissemination to the lung 
of cancer cells administered intrave-
nously, suggesting that CD13+ BMDCs 
promote angiogenesis at both primary 
and secondary tumor sites. Moreover, the 
administration of CD45+CD11b+CD13+ 
myeloid cells isolated from TSA tumors 
grown in WT mice could by itself increase 
the number of blood vessels (as well as 
their pericyte coverage) that serving 
tumors implanted in KO mice. These 
CD45+CD11b+CD13+ cells, which con-
sisted mainly of macrophages, specifically 
localized to the tumor microenvironment 
and produced soluble pro-angiogenic fac-
tors such as matrix metallopeptidase 9 
(MMP9) and chemokine (C-C motif) 
ligand 2 (CCL2, also known as MCP1). 
Given that both MMP9 and CCL2 are 
known to recruit pericytes, hence consoli-
dating vascular architecture, these find-
ings indicate that CD13+ myeloid BMDCs 
are likely to sustain tumor progression by 
attracting pericytes and thus promoting 
angiogenesis and vascular maturation.
Our findings establish CD13+ 
BMDCs as a previously unrecognized 
non-malignant candidate for the develop-
ment of new anticancer therapies. CD13 
inhibitors and neutralizing antibod-
ies have previously been shown to limit 
angiogenesis and hence inhibit tumor 
growth.8-10 Our observation that CD13+ 
BMDCs are almost exclusively localized 
within neoplastic lesions makes them an 
attractive target for ligand-directed deliv-
ery of biological response modifiers and/
or drugs. For example, CD13 ligands as 
well as molecules that bind other recep-
tors selectively expressed by CD13+ 
BMDCs could be exploited for the tar-
geted delivery of cytotoxic compounds. 
Interestingly, previous studies have 
shown that CD13 is expressed in different 
immunoreactive forms by tumor-asso-
ciated blood vessels, myeloid cells, and 
epithelial cells, and that the vasculature-
associated variant of CD13 is selectively 
recognized by peptides containing an 
NGR motif.8-10 This very small domain, 
which we identified by in vivo phage 
display technology, has been exploited 
to selectively deliver chemotherapeutic 
drugs, cytokines, pro-apoptotic peptides, 
liposomes, viruses, vascular-targeting, 
and/or imaging agents to tumor blood 
vessels, resulting in significant therapeu-
tic responses or improvements in imaging 
procedure.8-10 Although CD13+ BMDCs 
are not recognized by NGR-containing 
ligands, perhaps as they express a form 
of CD13 that differs from that found on 
endothelial cells and/or owing to vas-
cular accessibility issues, other ligands 
targeting the BMDC-associated vari-
ant of CD13 or other markers might be 
developed to target this cell subset, as 
previously accomplished with endothe-
lial cells. In summary, the discovery that 
CD13+ BMDCs promote tumor growth 
and angiogenesis has potential therapeu-
tic implications that merit further inves-
tigation. If our finding were confirmed 
in translational settings, this newly rec-
ognized cell subpopulation could serve as 
a non-malignant target for the develop-
ment of novel anticancer therapies.
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Figure 1. experimental tumor models used to study the function of CD13+ bone marrow-derived 
cells. (A) wild-type (wT) and CD13-null (KO) mice were irradiated and transplanted with wild-type 
(wt) or CD13-null (ko) bone marrow-derived cells (BMDCs) recovered from wT and KO mice (donors), 
as indicated. Bone marrow-transplanted (BMT) mice were then subcutaneously implanted with 
syngeneic cancer (melanoma, mammary adenocarcinoma, or lung carcinoma) cells. (B and C) 
Tumor growth was severely impaired in mice lacking CD13+ BMDCs (KOko and wTko mice), correlat-
ing with a reduction in both vascular density and pericyte coverage within neoplastic lesions.www.landesbioscience.com OncoImmunology  e27716-3
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